Enanta在2025年10月2日关闭之前,筹集了6 500万美元规模大的股票供应。 Enanta raises $65 million in upsized stock offering set to close Oct. 2, 2025.

Enanta制药公司以每股100美元的价格向公众大规模提供650万股的股票,在开销前筹集了6 500万美元。 Enanta Pharmaceuticals has priced an upsized public offering of 6.5 million shares at $10.00 each, raising $65 million before expenses. 预计这项提议将于2025年10月2日结束,其中包括一个30天的期权,供承保人购买975 000个额外股份。 The offering, expected to close on October 2, 2025, includes a 30-day option for underwriters to buy 975,000 additional shares. 摩根大通、富瑞和 Evercore ISI 是牵头经办人。 J.P. Morgan, Jefferies, and Evercore ISI are lead managers. 提议方使用于2023年11月提交并于2024年2月生效的交存登记书。 The offering uses a shelf registration filed in November 2023 and effective in February 2024. Enanta以病毒学和免疫学为重点,开发RSV和炎症的治疗方法,其C型丙型肝炎药物Glecaprevir的特许使用费收入支持其工作。 Enanta, focused on virology and immunology, develops treatments for RSV and inflammatory diseases, with royalty income from its hepatitis C drug Glecaprevir supporting its work. 前瞻性报表有在证交会申报中详细列明的风险。 Forward-looking statements are subject to risks detailed in SEC filings.